Company Description:
Architecture firm
Architecture firm
Construction Executive Online
Construction Job Openings
Company News
- Parallel Systems, Maker of Self-Powered Railcars, Lands $38 Million - WSJ (news.google.com)
- (PDF) The efficacy of immunonutrition in improving tolerance to chemoradiotherapy in patients with head and neck cancer, receiving nutritional counseling: study protocol of a randomized, open-label, parallel group, bicentric pilot study - ResearchGate (news.google.com)
- Medical Device Coverage Initiatives: Connecting with Payors via the Payor Communication Task Force - fda.gov (news.google.com)
- Clearside Biomedical Announces Additional Data from the CLS-AX ODYSSEY Phase 2b Trial Presented at the Angiogenesis, Exudation, and Degeneration 2025 Meeting - Yahoo Finance (news.google.com)
- (PDF) CONSORT 2010 statement: updated Guidelines for Reporting Parallel Group Randomised Trials - ResearchGate (news.google.com)
- iCapital® to Acquire Parallel Markets to Streamline Digital Identity, Investment Onboarding, and Compliance Verification - Business Wire (news.google.com)
- Improved motor imagery skills after repetitive passive somatosensory stimulation: a parallel-group, pre-registered study - Frontiers (news.google.com)
- (PDF) Add-on imeglimin versus metformin dose escalation regarding glycemic control in patients with type 2 diabetes treated with a dipeptidyl peptidase-4 inhibitor plus low-dose metformin: study protocol for a multicenter, prospective, randomized, open-label, - ResearchGate (news.google.com)
- Maga Inc: how Donald Trump’s allies stand to gain from ‘anti-woke’ resurgence - Financial Times (news.google.com)
- Former Surterra Wellness executives sue Wrigley over overvalued stock payments - Crain's Chicago Business (news.google.com)
- Parallel’s legal discovery exposes executive attempts to put out fires - Crain's Chicago Business (news.google.com)
- (PDF) POS-144 A PHASE 1, OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, PARALLEL GROUP SAFETY AND BIOAVAILABILITY STUDY OF BION-1301 ADMINISTERED BY INTRAVENOUS (IV) AND SUBCUTANEOUS (SC) ROUTES - ResearchGate (news.google.com)
- Comparison of protective effects of teneligliptin and luseogliflozin on pancreatic β-cell function: randomized, parallel-group, multicenter, open-label study (SECRETE-I study) - Frontiers (news.google.com)
- Parallel Life Studios creates the future of costuming for movies, TV... and fandom, as well - Popverse (news.google.com)
- Cheetah Net Supply Chain Service Inc. Announces Second Quarter 2024 Results and Provides Corporate Update - GlobeNewswire (news.google.com)
- Effects of Assist-As-Needed Upper Extremity Robotic Therapy after Incomplete Spinal Cord Injury: A Parallel-Group Controlled Trial - Frontiers (news.google.com)
- Parallel Cannabis settles its $7.4 million case with Legacy Knight - Crain's Chicago Business (news.google.com)
- SNDL pushes ahead with Parallel, Skymint buys despite litigation - Crain's Chicago Business (news.google.com)
- Parallel shareholders continue fight against restructuring plan - Crain's Chicago Business (news.google.com)
- Rise in Active RaaS Groups Parallel Growing Victim Counts: Ransomware in 2H 2023 - Trend Micro (news.google.com)
- The differential effect of two cereal foods on gut environment: a randomized, controlled, double-blind, parallel-group study - Frontiers (news.google.com)
- Gaboxadol in Fragile X Syndrome: A 12-Week Randomized, Double-Blind, Parallel-Group, Phase 2a Study - Frontiers (news.google.com)
- Parallel gets new funding for its teletherapy platform for kids with special needs - TechCrunch (news.google.com)
- Parallel Wireless is back, boasting a cloud RAN breakthrough - Light Reading (news.google.com)
- Parallel Stockholders Reject Proposed Restructuring in Billion-Dollar Lawsuit - Crain's Chicago Business (news.google.com)
- Conservatives Are Spending Millions To Build A ‘Parallel Economy’ Of Anti-Woke Businesses - Forbes (news.google.com)
- Empagliflozin and colchicine in patients with reduced left ventricular ejection fraction following ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: a study protocol for a randomized, double-blinded, three-arm parallel-gr - BioMed Central (news.google.com)
- SunStream USA Launches as a Result of Restructuring of Parallel - PR Newswire (news.google.com)
- Parallel Raises $1.85 Million Pre-Seed Investment - TechBuzz News (news.google.com)
- Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study - The Lancet (news.google.com)
- Parallel’s Investor Suit Against Wrigley Allowed to Move Forward - Crain's Chicago Business (news.google.com)
- (PDF) A Randomized, Controlled, Parallel-Group, Trial on the Long-term Effects of Melatonin on Fatigue Associated With Breast Cancer and Its Adjuvant Treatments - ResearchGate (news.google.com)
- Ultrasound-guided percutaneous electrical nerve stimulation versus surgery for women with unilateral carpal tunnel syndrome: A randomized parallel-group trial - Wiley Online Library (news.google.com)
- Parent-led massage and sleep EEG for term-born infants: A randomized controlled parallel-group study - Wiley Online Library (news.google.com)
- MIRAILAB BIOSCIENCE Inc., the Leading Company in NMN Supplements Announces Health Mailing Kit Series - Business Wire (news.google.com)
- Recruiting Underway in FSD Pharma’s Phase 2 Trial of FSD-PEA (FSD201) for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD) - Business Wire (news.google.com)
- Parallel Advisors Partners with Golden Gate Capital on Recapitalization - Business Wire (news.google.com)
- Apollo Global to Sell Tower Operator Parallel to Palistar-Backed Company - WSJ (news.google.com)
- Marijuana MSO Parallel faces financial hurdles after $1.9B SPAC deal collapses - MJBizDaily (news.google.com)
- ‘Huge firings’ at Parallel Wireless as CEO blames economic conditions - Capacity Media (news.google.com)
- Digital Health Platform Parallel Learning Announces $20M in Series A Funding to Further Expand and Serve Students with Learning and Thinking Differences - Business Wire (news.google.com)
- Chronic Consumption of Cranberries (Vaccinium macrocarpon) for 12 Weeks Improves Episodic Memory and Regional Brain Perfusion in Healthy Older Adults: A Randomised, Placebo-Controlled, Parallel-Groups Feasibility Study - Frontiers (news.google.com)
- Investors Sue Parallel for Alleged Securities Fraud Scheme - Cannabis Business Times (news.google.com)
- Parallel Learning Expands To Empower Students With Disabilities - Forbes (news.google.com)
- Parallel Systems Emerges From Stealth With $50 Million For Autonomous Electric Trains—But Will Its Plan Work? - dot.LA (news.google.com)
- Parallel Separates the Chairman and CEO Roles - PR Newswire (news.google.com)
- Parallel Announces Opening of Its First goodblend™ Retail Store in Pennsylvania - PR Newswire (news.google.com)
- Parallel, Japan’s answer to Discord, secures $11M series B for global expansion - thebridge.jp (news.google.com)
- Figure 3. Figure 3. Stabilizer TM (Chattanooga Group Inc.), the... - ResearchGate (news.google.com)
- Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic e - BioMed Central (news.google.com)
- Parallel Enters Deal with SPAC, Eyes on Going Public - Ganjapreneur - Ganjapreneur (news.google.com)
- Billionaire Beau Wrigley Says His Cannabis Company Will Be Bigger Than The Family Candy Business - Forbes (news.google.com)
- An open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2) - Nature (news.google.com)
- A multicentre, randomised, open-label, parallel-group Phase 2b study of belotecan versus topotecan for recurrent ovarian cancer - Nature (news.google.com)
- Parallel's Surterra Wellness Brand Announces Corporate Partnership with Cannabis LAB - PR Newswire (news.google.com)
- Clinical evaluation of the pharmacological impact of ashwagandha root extract on sleep in healthy volunteers and insomnia patients: A double-blind, randomized, parallel-group, placebo-controlled study - ScienceDirect.com (news.google.com)
- Tolerability and efficacy of vortioxetine versus SSRIs in elderly with major depression. Study protocol of the VESPA study: a pragmatic, multicentre, open-label, parallel-group, superiority, randomized trial - BioMed Central (news.google.com)
- A single-centre investigator-blinded randomised parallel-group study protocol to investigate the influence of an acclimatisation appointment on children’s behaviour during N2O/O2 sedation as measured by psychological, behavioural and real-time physiologic - Nature (news.google.com)
- Gefapixant, a P2X3 receptor antagonist, for the treatment of refractory or unexplained chronic cough: a randomised, double-blind, controlled, parallel-group, phase 2b trial - The Lancet (news.google.com)
- Delta’s ‘parallel reality’ display sounds like sci-fi, but it’s coming soon - Fast Company (news.google.com)
- Surterra Wellness Announces Corporate Name Change to Parallel™ Effective Today - PR Newswire (news.google.com)
- Carotid artery plaque intervention with Tongxinluo capsule (CAPITAL): A multicenter randomized double-blind parallel-group placebo-controlled study - Nature (news.google.com)
- Parallel Wireless | PRESS OFFICE: - IT News Africa (news.google.com)
- ‘Parallel reality’ display technology startup Misapplied Sciences raises more cash - GeekWire (news.google.com)
- 49th Parallel Coffee Roasters® and Claridge Announce Strategic Partnership - markets.businessinsider.com (news.google.com)
- 49th Parallel Coffee Roasters® and Claridge Announce Strategic Partnership - Newswire.ca (news.google.com)
- Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled t - The Lancet (news.google.com)
- CBi2 Capital and 51st Parallel Announce the Creation of - GlobeNewswire (news.google.com)
- Mind-bending new screen technology uses 'magic pixel' to display different content to multiple people - GeekWire (news.google.com)
- Tiotropium and olodaterol in the prevention of chronic obstructive pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial - The Lancet (news.google.com)
- 51st Parallel Inc. Completes Equity Financing to Fully Fund its Alberta Focused, Vertically Integrated Cannabis Business Plan and Announces Strategic Partnership with LivWell Enlightened Health - Newswire.ca (news.google.com)
- (PDF) Understanding Cross Over and Parallel group studies in Drug Research - ResearchGate (news.google.com)
- (PDF) Matured hop extract reduces body fat in healthy overweight humans: A randomized, double-blind, placebo-controlled parallel group study - ResearchGate (news.google.com)
- Nocturnal non-invasive ventilation in COPD patients with prolonged hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study - The BMJ (news.google.com)